OBP-301 is a genetic treatment using adenovirus target specifically to cancer cells only. When entering into cancer cells, virus particles disrupt the infected cancer cells from proliferating.
OBP-301 is co-developed by MBC and Oncolys BioPharma Inc. from Japan. Phase I dose-escalation study was conducted by Oncolys in US targeting patients with various solid tumors. It was completed in 2008 with proven safety consist of 22 patients enrolled in the study. MBC and Oncolys are currently joint effort to conduct phase I/II study in Taiwan and Korea.